CERo Therapeutics (CERO) Competitors $0.06 +0.00 (+3.89%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CERO vs. RNXT, PMN, LIAN, NXTC, KALA, DRRX, FBRX, DARE, LGVN, and LPCNShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include RenovoRx (RNXT), ProMIS Neurosciences (PMN), LianBio (LIAN), NextCure (NXTC), KALA BIO (KALA), DURECT (DRRX), Forte Biosciences (FBRX), Daré Bioscience (DARE), Longeveron (LGVN), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. RenovoRx ProMIS Neurosciences LianBio NextCure KALA BIO DURECT Forte Biosciences Daré Bioscience Longeveron Lipocine RenovoRx (NASDAQ:RNXT) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends. Do analysts rate RNXT or CERO? RenovoRx presently has a consensus price target of $6.50, indicating a potential upside of 420.00%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts clearly believe RenovoRx is more favorable than CERo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, RNXT or CERO? RenovoRx has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Is RNXT or CERO more profitable? CERo Therapeutics' return on equity of 0.00% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -205.96% -110.01% CERo Therapeutics N/A N/A -108.43% Does the media favor RNXT or CERO? In the previous week, CERo Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat CERo Therapeutics' score of -0.31 indicating that RenovoRx is being referred to more favorably in the media. Company Overall Sentiment RenovoRx Neutral CERo Therapeutics Neutral Which has higher earnings and valuation, RNXT or CERO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRxN/AN/A-$10.23M-$0.57-2.19CERo TherapeuticsN/AN/A-$2.54MN/AN/A Do institutionals and insiders believe in RNXT or CERO? 3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by insiders. Comparatively, 18.0% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor RNXT or CERO? RenovoRx received 9 more outperform votes than CERo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRenovoRxOutperform Votes947.37% Underperform Votes1052.63% CERo TherapeuticsN/AN/A SummaryRenovoRx and CERo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.43M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7389.8217.18Price / SalesN/A415.011,116.21116.95Price / CashN/A182.1042.8937.86Price / Book-0.023.894.784.78Net Income-$2.54M-$42.21M$120.23M$225.60M7 Day PerformanceN/A-2.15%-1.92%-1.23%1 Month PerformanceN/A4.20%11.49%3.36%1 Year PerformanceN/A18.39%30.57%16.60% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo TherapeuticsN/A$0.06+3.9%N/AN/A$8.43MN/A0.008RNXTRenovoRx1.2324 of 5 stars$1.25-2.4%$6.50+420.5%+76.1%$29.97MN/A-2.256Positive NewsGap UpPMNProMIS Neurosciences1.0623 of 5 stars$0.91-2.1%N/A-20.2%$29.75M$10,000.00-9.306Positive NewsLIANLianBioN/A$0.27flat$3.50+1,194.4%-94.2%$29.22MN/A-0.33110NXTCNextCure4.2168 of 5 stars$1.02-5.6%$4.00+292.2%-14.9%$28.57MN/A-0.5290Positive NewsKALAKALA BIO3.8466 of 5 stars$6.17-0.2%$15.00+143.1%-13.3%$28.44M$3.89M-0.5030Gap DownDRRXDURECT2.6267 of 5 stars$0.91+21.4%$5.00+449.2%+89.2%$28.26M$8.59M-1.3980Analyst ForecastNews CoverageFBRXForte Biosciences1.6802 of 5 stars$19.05-17.7%$23.58+23.8%+65,237.8%$27.81MN/A-1.315DAREDaré Bioscience1.5891 of 5 stars$3.18flat$24.00+654.7%-31.1%$27.67M$1.88M-5.3930Analyst ForecastGap DownLGVNLongeveron3.4375 of 5 stars$1.85-0.8%$8.67+369.7%-89.8%$27.37M$1.89M-0.3023LPCNLipocine1.5291 of 5 stars$4.96-1.2%$10.00+101.6%+63.4%$26.53M$7.92M-6.6110News Coverage Related Companies and Tools Related Companies RNXT Alternatives PMN Alternatives LIAN Alternatives NXTC Alternatives KALA Alternatives DRRX Alternatives FBRX Alternatives DARE Alternatives LGVN Alternatives LPCN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CERO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
